A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of Daily OCID 4681-S-01 Administered Orally to Subjects with Advanced Solid Tumors.
Latest Information Update: 03 Jul 2019
Price :
$35 *
At a glance
- Drugs OCID 4681-S-01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Orchid Chemicals & Pharmaceuticals
- 21 Jan 2012 New trial record